Literature DB >> 21496627

Dysferlinopathies.

Anthony A Amato1, Robert H Brown.   

Abstract

Dysferlin is a sarcolemmal protein that plays an important role in patching defects in skeletal membrane by regulating vesicle fusion with the sarcolemma. Mutations in the dysferlin gene can lead to a variety of clinical phenotypes. Affected individuals usually present with early involvement of the posterior calf muscles (Miyoshi myopathy) in their teens or early twenties, but can present with proximal greater than distal weakness similar to other limb-girdle muscular dystrophies (LGMD2B), with anterior tibial weakness, an axial myopathy (e.g., rigid spine syndrome or hyperkyphosis resembling bent spine syndrome), or any combination of the above. Muscle biopsies may be quite inflammatory, often resulting in a misdiagnosis as polymyositis. Unfortunately, there are no medical therapies available at this time.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21496627     DOI: 10.1016/B978-0-08-045031-5.00007-4

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  15 in total

Review 1.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

2.  ["Therapy-resistant polymyositis" - is the diagnosis correct?]

Authors:  G Ceccon; H C Lehmann; E Neuen-Jacob; G Meng; G R Fink; G Wunderlich
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

3.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

4.  The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands.

Authors:  Kitipong Uaesoontrachoon; Hee-Jae Cha; Beryl Ampong; Arpana Sali; Jack Vandermeulen; Benjamin Wei; Brittany Creeden; Tony Huynh; James Quinn; Kathleen Tatem; Sree Rayavarapu; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  J Pathol       Date:  2013-10       Impact factor: 7.996

5.  The C2 domains of dysferlin: roles in membrane localization, Ca2+ signalling and sarcolemmal repair.

Authors:  Joaquin Muriel; Valeriy Lukyanenko; Tom Kwiatkowski; Sayak Bhattacharya; Daniel Garman; Noah Weisleder; Robert J Bloch
Journal:  J Physiol       Date:  2022-03-08       Impact factor: 6.228

6.  Assessment of disease activity in muscular dystrophies by noninvasive imaging.

Authors:  Katie K Maguire; Leland Lim; Sedona Speedy; Thomas A Rando
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

Review 7.  Triadopathies: an emerging class of skeletal muscle diseases.

Authors:  James J Dowling; Michael W Lawlor; Robert T Dirksen
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

8.  Insights into lipid accumulation in skeletal muscle in dysferlin-deficient mice.

Authors:  Anil K Agarwal; Katie Tunison; Matthew A Mitsche; Jeffrey G McDonald; Abhimanyu Garg
Journal:  J Lipid Res       Date:  2019-10-25       Impact factor: 5.922

9.  Genetic silencing of Nrf2 enhances X-ROS in dysferlin-deficient muscle.

Authors:  Ponvijay Kombairaju; Jaclyn P Kerr; Joseph A Roche; Stephen J P Pratt; Richard M Lovering; Thomas E Sussan; Jung-Hyun Kim; Guoli Shi; Shyam Biswal; Christopher W Ward
Journal:  Front Physiol       Date:  2014-02-19       Impact factor: 4.566

10.  FER-1/Dysferlin promotes cholinergic signaling at the neuromuscular junction in C. elegans and mice.

Authors:  Predrag Krajacic; Emidio E Pistilli; Jessica E Tanis; Tejvir S Khurana; S Todd Lamitina
Journal:  Biol Open       Date:  2013-10-15       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.